Select publications

Publications discussed by Dr Robert

Buzdar A. The ATAC (‘arimidex’, tamoxifen, alone or in combination) trial in postmenopausal women with early breast cancer – updated efficacy results based on a median follow-up of 47 months. Breast Cancer Res Treat 2002; Abstract 13.

Citron ML. et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup trial C9741/Cancer and Leukemia Group B trial 9741. J Clin Oncol 2003;21(7):1-9. Abstract

Fisher B et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J. Natl Cancer Inst 1998;90(18):1371-88. Abstract

Fountzilas G at al. First-line chemotherapy with paclitaxel by three-hour infusion and carboplatin in advanced breast cancer (final report): A phase II study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 1998; 9(9):1031-4. Abstract

Loesch D et al. Phase II multicenter trial of a weekly paclitaxel and carboplatin regimen in patients with advanced breast cancer. J Clin Oncol 2002; 20(18): 3857-64. Abstract

Perez, E et al. A phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast carcinoma. Cancer 2000; 88(1):124-31. Abstract

Slamon DJ et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl J Med 2001;344(11):783-92. Abstract

Trastuzumab/chemotherapy combinations in metastatic breast cancer

Baselga J. Current and planned clinical trials with trastuzumab (Herceptin). Semin Oncol 2000;27(5 Suppl 9):27-32. Abstract

Bell R. Ongoing trials with trastuzumab in metastatic breast cancer. Ann Oncol 2001;12 Suppl 1:S69- 73. Abstract

Burris HA 3rd. Docetaxel (Taxotere) in HER-2-positive patients and in combination with trastuzumab (Herceptin). Semin Oncol 2000;27(2 Suppl 3):19-23. Abstract

Burris HA 3rd. Docetaxel (Taxotere) plus trastuzumab (Herceptin) in breast cancer. Semin Oncol 2001;28(1 Suppl 3):38-44. Abstract

Crown J. Nonanthracycline containing docetaxel-based combinations in metastatic breast cancer. Oncologist 2001;6 Suppl 3:17-21. Abstract

Crown JP. The platinum agents: A role in breast cancer treatment? Semin Oncol 2001;28(1 Suppl 3):28- 37. Abstract

Esteva FJ et al. Chemotherapy of metastatic breast cancer: What to expect in 2001 and beyond. Oncologist 2001;6(2):133-46. Abstract

Fornier M et al. Trastuzumab in combination with chemotherapy for the treatment of metastatic breast cancer. Semin Oncol 2000;27(6 Suppl 11):38-45; discussion 92-100. Abstract

Gilewski T et al. An immunotherapeutic approach to treatment of breast cancer: Focus on trastuzumab plus paclitaxel. Breast Cancer Medicine Service. Cancer Chemother Pharmacol 2000;46 Suppl:S23-6. Abstract

Hortobagyi GN. Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer. Semin Oncol 2001;28(6 Suppl 18):43-7. Abstract

Ligibel JA, Winer EP. Trastuzumab/chemotherapy combinations in metastatic breast cancer. Semin Oncol 2002;29(3 Suppl 11):38-43. Abstract

Loesch D et al. Phase II multicenter trial of a weekly paclitaxel and carboplatin regimen in patients with advanced breast cancer. J Clin Oncol 2002;20(18):3857-64. Abstract

Martin M. Platinum compounds in the treatment of advanced breast cancer. Clin Breast Cancer 2001;2(3):190-208; discussion 209. Abstract

Nabholtz JM, Slamon D. New adjuvant strategies for breast cancer: Meeting the challenge of integrating chemotherapy and trastuzumab (Herceptin). Semin Oncol 2001;28(1 Suppl 3):1-12. Abstract

Pegram MD. Docetaxel and herceptin: Foundation for future strategies. Oncologist 2001;6 Suppl 3:22- 5. Abstract

Pegram MD et al. Trastuzumab and chemotherapeutics: Drug interactions and synergies. Semin Oncol 2000;27(6 Suppl 11):21-5; discussion 92-100. Abstract

Perez EA, Hortobagyi GN. Ongoing and planned adjuvant trials with trastuzumab. Semin Oncol 2000;27(6 Suppl 11):26-32; discussion 92-100. Abstract

Robert N et al. Phase III comparative study of trastuzumab and paclitaxel with and without carboplatin in patients with HER-2/neu positive breast cancer. Breast Ca Res Treat 2002;Abstract 35.

Slamon DJ et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344(11):783-92. Abstract

Slamon D, Pegram M. Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Semin Oncol 2001;28(1 Suppl 3):13-9. Abstract

Sparano JA. Cardiac toxicity of trastuzumab (Herceptin): Implications for the design of adjuvant trials. Semin Oncol 2001;28(1 Suppl 3):20-7. Abstract

Spigel DR, Burstein HJ. HER2 overexpressing metastatic breast cancer. Curr Treat Options Oncol 2002;3(2):163-74. Abstract

Thomssen C. Trials of new combinations of Herceptin in metastatic breast cancer. Anticancer Drugs 2001;12 Suppl 4:S19-25. Abstract

Van Pelt AE et al. Phase II study of neoadjuvant trastuzumab plus docetaxel for locally advanced and metastatic breast cancer that overexpresses HER2/neu: A preliminary report. Breast Cancer Res Treat 2002:Abstract 441.

Yardley DA et al. Final results of the Minnie Pearl Cancer Research Network first-line trial of weekly paclitaxel/carboplatin/trastuzumab in metastatic breast cancer. Breast Cancer Res Treat 2002;Abstract 439.

Home · Search